Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727017 | 0.86 | ALDH1A1 (0.59) | ALDH1A1PTGS2HTTPOLBSMN1; SMN2 | |
| SCHEMBL6825248 | 0.83 | ALDH1A1 (0.47) | ALDH1A1PTGS2P2RX7HTTPOLB | |
| SCHEMBL6715700 | 0.77 | ALDH1A1 (0.43) | ALDH1A1PTGS2P2RX7HTTPOLB | |
| SCHEMBL6714089 | 0.77 | ATM (0.55) | ALDH1A1HTTPOLBSMN1; SMN2LMNA | |
| SCHEMBL6715855 | 0.72 | ALDH1A1 (0.58) | ALDH1A1PTGS2HTTPOLBSMN1; SMN2 | |
| SCHEMBL11423763 | 0.72 | NLRP3 (0.52) | ALDH1A1PTGS2HTTPOLBSMN1; SMN2 | |
| SCHEMBL12812272 | 0.71 | POLB (0.65) | ALDH1A1PTGS2HTTPOLBSMN1; SMN2 | |
| SCHEMBL6715688 | 0.71 | CXCL8 (0.51) | PTGS2 | |
| SCHEMBL22169188 | 0.70 | PTGS2 (0.51) | ALDH1A1PTGS2HTTPOLBSMN1; SMN2 | |
| SCHEMBL6717218 | 0.70 | MAPK1 (0.50) | NLRP3LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | ALDH1A1 572/4885PTGS2 1056/4885P2RX7 1776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.